Insmed reported $-253876000 in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
DBV Technologies USD -41110000 14.49M Jun/2025
Dynavax Technologies USD 10.86M 34.49M Jun/2025
Gilead Sciences USD 2.7B 467M Jun/2025
Insmed USD -253876000 5.74M Jun/2025
Novartis USD 5.46B 2.06B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025